Evidence map›Paper›PMID 34719342›Full record

ArticlemAbs

Identification of a CE-SDS shoulder peak as disulfide-linked fragments from common C

Mingyan Cao, Yang Jiao, Conner Parthemore, Samuel Korman, Jiao Ma, Alan Hunter, Greg Kilby, Xiaoyu Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mingyan CaoAnalytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0001-5277-4962
Yang JiaoAnalytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Conner ParthemoreAnalytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Samuel KormanAnalytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Jiao MaAnalytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Alan HunterPurification Process Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Greg KilbyAnalytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Xiaoyu ChenAnalytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
AstraZeneca (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragmentation is a well-characterized degradation pathway of therapeutic antibodies and is usually monitored by capillary electrophoresis-sodium dodecyl sulfate (CE-SDS). Although fragments due to cleavage in C

Indexed as

Antibodies, BispecificAntibodies, MonoclonalDisulfidesElectrophoresis, CapillaryImmunoglobulin GSodium Dodecyl SulfateAntibodies, BispecificAntibodies, MonoclonalDisulfidesImmunoglobulin GSodium Dodecyl SulfateCE-SDSfragmentshydrophobic interaction chromatographyIgG-like bispecific antibodiesintrachain disulfide bondmonoclonal antibodypeptide mappingprotease inhibitorsubunit

Identifiers

PMID34719342
PMCPMC8565840
OpenAlexW3210963558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.